Contact Us
Drug Search Results
More Filters [+]

Rivoglitazone

Alternative Names: rivoglitazone, de-101, de101, de 101
Latest Update: 2024-03-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: PPAR-g Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rivoglitazone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Type 2 Diabetes

Phase 2: Keratoconjunctivitis Sicca|Type 2 Diabetes|Dry Eye Syndromes|Dry Eye Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT01468168

P2

Completed

Dry Eye Syndromes|Keratoconjunctivitis Sicca|Dry Eye Disease

2012-11-01

NCT01118754

P2

Completed

Keratoconjunctivitis Sicca|Dry Eye Syndromes

2010-12-01

JapicCTI-090916

P2

Completed

Keratoconjunctivitis Sicca

2010-10-31

JapicCTI-090877

P2

Completed

Keratoconjunctivitis Sicca

2009-08-31

Recent News Events

Date

Type

Title

03/05/2024

News Article

 An Original Culinary Travel and History Series Exploring the Vibrant, Untold Food Stories Hidden in Rural and Small-town America

11/01/2023

PubMed

 Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices.

03/27/2023

PubMed

 Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant Sisymbrium irio L.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions